Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group.
about
Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's diseaseThe role of maintenance therapy in multiple myelomaPrevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis.Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients.Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) and interferon-alpha with melphalan and prednisone (MP) and interferon-alpha (IFN-alpha) in patients with good-prognosis multiple myeloma: a prospective randomizeDevelopment of an EORTC questionnaire module to be used in health-related quality-of-life assessment for patients with multiple myeloma. European Organization for Research and Treatment of Cancer Study Group on Quality of Life.Therapeutic options in the treatment of multiple myeloma: pharmacoeconomic and quality-of-life considerations.On the evolution of statistical methods as applied to clinical trials.Nordic Myeloma Study Group, the first 15 years: scientific collaboration and improvement of patient care.Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized studyA randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial.Methodological issues related to assessing and measuring quality of life in patients with cancer: implications for patient care.Quality of life and supportive care in multiple myeloma.A systematic review of health-related quality of life in longitudinal studies of myeloma patients.Health-related quality of life and patients' perceptions in interferon-treated multiple myeloma patients. Nordic Myeloma Study Group.Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma.Diagnosis and management of multiple myeloma.Responsiveness and minimal important score differences in quality-of-life questionnaires: a comparison of the EORTC QLQ-C30 cancer-specific questionnaire to the generic utility questionnaires EQ-5D and 15D in patients with multiple myeloma.Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions.Psychological reactions and quality of life in patients with posterior uveal melanoma treated with ruthenium plaque therapy or enucleation: a one year follow-up study.Health-related quality of life in patients with endocrine tumours of the gastrointestinal tract.Quality of life may be affected more by disease parameters and response to therapy than by haemoglobin changes.Health-related quality of life measured by the EORTC QLQ-C30--reference values from a large sample of Swedish population.Guidelines on the diagnosis and management of multiple myeloma 2005.
P2860
Q24203739-94375945-E09F-4B11-AD25-E598F5BD421CQ28071644-7702B32D-EB69-419F-A080-D6EE22C0D6B7Q30248483-C3A1E12D-DDE1-4DD8-ADDC-26AE39A96168Q30655745-BCC2058F-0594-4357-A0B2-EBEED1130E6BQ31899323-856A3CFD-F19E-4113-AFEE-6C4ED7F1D89FQ33543722-B8F26C80-B471-422F-9578-5503A5D97C92Q33809965-82348A1A-44E1-4607-943A-96C41E8EAE51Q35743841-819EE2F1-06D5-49EF-9647-0226BC892441Q36031589-CEE6D684-FC3D-4D4C-B35B-0BD19D9C13E8Q36382493-D5D69292-4171-4AFE-A67A-3BF579377F66Q36654092-7C5C8F05-A54B-4EA0-9F3D-90272EE33AACQ37053100-8A141298-1F22-4B60-A224-8F8BC118513AQ37426566-F3EF1774-A2D9-4ACD-9C46-1F7EB97BE1A3Q38742505-0FC83874-D7AE-4A03-AA17-1AF037043983Q40609841-625C24B4-C181-4223-987D-5D9B5016C16AQ43650924-07DA0339-CB80-4DC9-8711-285E05EA5FB0Q43817786-4BF59C96-B93E-4F3A-87A9-287025A40D31Q48651395-AD656619-520C-43EA-8CBB-063F4085D07DQ48660910-83EBDFF7-C4BA-454A-9C72-858E5B4F456EQ48682461-3D73428F-035F-45CA-B34B-802A005646EDQ51088925-D2528F9B-0562-4C96-8ECE-D58951DD364EQ53281428-455B277F-1F01-4237-A54C-DDA6F26E6C4BQ53510041-41834C66-EC03-44F1-8B78-C5F8FA73AFF3Q53556535-360A6A1A-EA5A-4B94-8667-49AD6E831D6C
P2860
Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Effect of interferon on the he ...... he Nordic Myeloma Study Group.
@en
type
label
Effect of interferon on the he ...... he Nordic Myeloma Study Group.
@en
prefLabel
Effect of interferon on the he ...... he Nordic Myeloma Study Group.
@en
P2093
P1476
Effect of interferon on the he ...... he Nordic Myeloma Study Group.
@en
P2093
P304
P356
10.1046/J.1365-2141.1996.D01-1802.X
P407
P50
P577
1996-08-01T00:00:00Z